TG Therapeutics, Inc. Announces Clinical Data Presentations at Upcoming Conferences

TG Therapeutics Logo

  • Single Agent Study Updates on TG-1101 and TGR-1202 to be Presented at ASCO 2014
  • Combination Study Data of TG-1101 plus Ibrutinib to be Presented at EHA 2014
  • Combination Study Data of TG-1101 and TGR-1202 to be Presented at the 2014 Pan Pacific Lymphoma Conference

NEW YORK, May 6, 2014 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX), today announced upcoming presentations of clinical data for TG-1101, the Company's next generation, glycoengineered anti-CD20 monoclonal antibody and for TGR-1202, the Company's novel, once-daily PI3k delta inhibitor, at various upcoming conferences this summer.

First, at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held from May 30 to June 3, 2014 in Chicago, Illinois, updated safety, efficacy, and pharmacokinetic data will be presented from TG Therapeutics' ongoing Phase 1 studies of TG-1101 and TGR-1202 as single agents in patients with advanced hematologic malignancies.

The presentation schedule at ASCO 2014 is as follows:

Poster Presentation & Discussion:

  • Title: Activity of TGR-1202, a novel once-daily PI3K delta inhibitor, in patients with relapsed or refractory hematologic malignancies.
    • Abstract Number: 2513
    • Presentation Date & Time: Friday, May 30, 2014, 1:00 PM - 4:00 PM CT
    • Poster Display: Room E354b, Poster Board #27
    • Presenter: Howard A. Burris, MD, Sarah Cannon Research Institute, Nashville, TN

      Discussion Session
    • 4:30 – 5:45 PM CT; E Arie Crown Theater

Poster Presentation:

  • Title: A phase I trial of ublituximab (TG-1101), a novel glycoengineered anti-CD20 monoclonal antibody in B-cell non-Hodgkin lymphoma patients with prior exposure to rituximab.
    • Abstract Number: 8524
    • Presentation Date & Time: Friday, May 30, 2014, 1:00 PM - 4:00 PM CT
    • Poster Display: Room S405, Poster Board #4
    • Presenter: Owen A. O'Connor, MD, PhD, Columbia University Medical Center, New York, NY

In addition, data from the first combination study of TG-1101 and ibrutinib as well as data from the single agent studies for both TG-1101 and TGR-1202 will be presented at the 19th Congress of the European Hematology Association (EHA) held June 12 – 15, 2014 in Milan, Italy.

Finally, a clinical update on the combination study of TG-1101 and TGR-1202 will be presented at the 2014 Pan Pacific Lymphoma Conference to be held in Hawaii on July 21 – 25, 2014. Further detail on presentations at EHA and Pan Pacific will be provided as specific presentation details are released by each of the conferences.

A copy of the ASCO abstracts will be available online on May 14, 2014 after 5:00pm ET through the ASCO meeting website at A copy of the EHA abstracts will be available online on May 21, 2014 through the EHA meeting website at Following each presentation, the posters will be available on the Company's website,, in the Publications section found under the Pipeline tab.


TG Therapeutics is an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the company is developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. TG Therapeutics is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical trials, the timing of commencing or completing such trials and business prospects for TG-1101 and TGR-1202 may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete pre-clinical and clinical trials for TG-1101 and TGR-1202; the risk that early pre-clinical and clinical results that supported our decision to move forward with TG-1101 and TGR-1202 will not be reproduced in additional patients or in future studies; the risk that TGR-1202 will not produce satisfactory safety and efficacy results to warrant further development following the completion of the current phase 1 study; the risk that the data (both safety and efficacy) from future clinical trials will not coincide with the data produced from prior pre-clinical and clinical trials; the risk that trials will take longer to enroll than expected; our ability to achieve the milestones we project over the next year; our ability to manage our cash in line with our projections, and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.


CONTACT: Jenna Bosco Director - Investor Relations TG Therapeutics, Inc. Telephone: 212.554.4351 Email:

Source:TG Therapeutics, Inc.